LOG IN
SIGN UP
MARKET
HRTX
HRTX
Heron Therapeutics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
3.260
+0.080
+2.52%
Opening 12:50 05/27 EDT
OPEN
3.200
PREV CLOSE
3.180
HIGH
3.330
LOW
3.125
VOLUME
747.24K
TURNOVER
1.17M
52 WEEK HIGH
16.63
52 WEEK LOW
3.050
MARKET CAP
334.08M
P/E (TTM)
-1.4203
1D
5D
1M
3M
1Y
5Y
Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that company management will p...
PR Newswire · 1d ago
Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today presented at the Society for Obstetric A...
PR Newswire · 05/16 20:05
--Cantor Fitzgerald Adjusts Price Target for Heron Therapeutics to $12 From $20, Maintains Overweight Rating
MT Newswires · 05/10 14:24
Needham Adjusts Heron Therapeutics' Price Target to $14 from $16, Keeps Buy Rating
MT Newswires · 05/10 09:06
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -40% and 6.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 22:45
BRIEF-Heron Therapeutics Qtrly Loss Per Share $0.63
reuters.com · 05/09 22:11
Heron Therapeutics GAAP EPS of -$0.63 misses by $0.15, revenue of $23.46M beats by $0.85M
Heron Therapeutics press release (NASDAQ:HRTX): Q1 GAAP EPS of -$0.63 misses by $0.15. Revenue of $23.46M (+17.2% Y/Y) beats by $0.85M.
Seekingalpha · 05/09 20:43
Heron Therapeutics Q1 EPS $(0.63) Down From $(0.58) YoY, Sales $23.46M Up From $20.02M YoY; Sees FY22 Net Sales Guidance $89M-$93M
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.63) per share. This is a 8.62 percent decrease over losses of $(0.58) per share from the same period last year. The company reported $23.46 million in
Benzinga · 05/09 20:33
No Data
Learn about the latest financial forecast of HRTX. Analyze the recent business situations of Heron Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 6 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
16.67%Strong Buy
83.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HRTX stock price target is 17.08 with a high estimate of 40.00 and a low estimate of 7.50.
Current 3.360
EPS
Actual
Estimate
-0.50-0.38-0.25-0.13
Institutional Holdings
Institutions: 294
Institutional Holdings: 140.27M
% Owned: 136.88%
Shares Outstanding: 102.48M
TypeInstitutionsShares
Increased
75
15.26M
New
22
474.45K
Decreased
45
10.82M
Sold Out
35
4.14M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Director
Barry Quart
President
John Poyhonen
Chief Operating Officer/Executive Vice President/IR Contact Officer
David Szekeres
Executive Vice President/Director
Kimberly Manhard
Senior Vice President/Chief Scientific Officer
Thomas Ottoboni
Senior Vice President/Director of Human Resources
Sean Ristine
Senior Vice President
Michael Mathews
Chief Accounting Officer/Vice President
Lisa Peraza
Vice President
John Arthur
Other
Christopher Storgard
Lead Director/Independent Director
Craig Johnson
Independent Director
Stephen Davis
Independent Director
Sharmila Dissanaike
Independent Director
Susan Rodriguez
Independent Director
Christian Waage
No Data
No Data
About HRTX
Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.
Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.